1. DOP39 Endoscopic, histologic, and combined outcomes with reinitiation of ozanimod after temporary discontinuation: 2-year interim analysis of the True North open-label extension study. (30th January 2023) Authors: Vermeire, S; Dignass, A; Colombel, J F; Jain, A; Canavan, J B; Wu, H; Lawlor, G; Osterman, M T; Rubin, D T; Regueiro, M Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i103 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. DOP43 Extended induction in the True North OLE study: ozanimod efficacy in biologic-naive and biologic-experienced patients. (30th January 2023) Authors: Dignass, A; Regueiro, M; Colombel, J F; Jain, A; Canavan, J B; Wu, H; Lawlor, G; Osterman, M T; Vermeire, S; Rubin, D T Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i110 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P609 Impact of prior biologic exposure on durability of recaptured response to ozanimod during the True North open-label extension study. (30th January 2023) Authors: Colombel, J F; Rubin, D T; Vermeire, S; Jain, A; Canavan, J B; Wu, H; Lawlor, G; Osterman, M T; Dignass, A; Regueiro, R Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i738 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P687 Durability of recaptured response to ozanimod during the True North open-label extension. (30th January 2023) Authors: Dignass, A; Regueiro, M; Colombel, J F; Jain, A; Canavan, J B; Wu, H; Lawlor, G; Osterman, M T; Vermeire, S; Rubin, D T Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i817 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P715 Achievement and maintenance of endoscopic, histologic, and combined outcomes after extended induction in Week 10 nonresponders of ozanimod: 2-year interim analysis of the True North open-label extension study. (30th January 2023) Authors: Vermeire, S; Colombel, J F; Rubin, D T; Ghosh, S; Jain, A; Lawlor, G; Osterman, M T; Wu, H; Canavan, J B; Chiorean, M V Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i844 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P773 Extended induction in the True North open-label extension study: clinical outcomes of ~2 years of ozanimod treatment. (30th January 2023) Authors: Vermeire, S; Colombel, J F; Chiorean, M V; Ghosh, S; Jain, A; Lawlor, G; Osterman, M T; Wu, H; Canavan, J B; Rubin, D T Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i903 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗